Fjar.ang.s, Sweden

Kjell Hjalmar Andersson

This inventor holds 5 USPTO granted patents. Top assignees: Aktiebolaget Hassle, Astra Aktiebolag. Active years: 1991-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kjell Hjalmar Andersson. Retrieved from https://idiyas.com/inventor/kjell-hjalmar-andersson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 56(Granted Patents)


Location History:

  • Fjaras, SE (1992)
  • Fjar.ang.s, SE (1991 - 1999)

Company Filing History:


Years Active: 1991-1999

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Kjell Hjalmar Andersson: A Pioneer in Pharmaceutical Innovations

Introduction

Kjell Hjalmar Andersson is a notable inventor based in Fjar.ang.s, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. With a total of 5 patents to his name, Andersson's work has had a lasting impact on the industry.

Latest Patents

Among his latest patents are advancements in short-acting dihydropyridines and pharmaceutical emulsions. These innovations reflect his commitment to improving drug efficacy and patient outcomes. His research has paved the way for new therapeutic options in the pharmaceutical market.

Career Highlights

Throughout his career, Andersson has worked with prominent companies such as Aktiebolaget Hassle and Astra Aktiebolag. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking projects in the pharmaceutical sector.

Collaborations

Andersson has collaborated with esteemed colleagues, including Margareta Nordlander and Rolf Christer Westerlund. These partnerships have fostered a collaborative environment that has led to significant advancements in their respective fields.

Conclusion

Kjell Hjalmar Andersson's contributions to pharmaceutical innovations are commendable. His patents and collaborations highlight his dedication to advancing medical science. His work continues to influence the industry and improve patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…